222 related articles for article (PubMed ID: 35809794)
1. The role of central nervous system (CNS) prophylaxis in preventing DLBCL patients from CNS relapse: A network meta-analysis.
Lin Z; Chen X; Liu L; Zeng H; Li Z; Xu B
Crit Rev Oncol Hematol; 2022 Aug; 176():103756. PubMed ID: 35809794
[TBL] [Abstract][Full Text] [Related]
2. Prophylaxis strategies containing high dose intravenous methotrexate on preventing CNS relapse for patients with diffuse large B-cell lymphoma at intermediate to high risk: A study based on 12 cohorts in the rituximab era.
Zhang N; Xu D; Liu B; Shi X; Xie X; Wang Z
Int Immunopharmacol; 2022 Dec; 113(Pt A):109299. PubMed ID: 36252471
[TBL] [Abstract][Full Text] [Related]
3. Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients.
Wilson MR; Eyre TA; Kirkwood AA; Wong Doo N; Soussain C; Choquet S; Martinez-Calle N; Preston G; Ahearne M; Schorb E; Moles-Moreau MP; Ku M; Rusconi C; Khwaja J; Narkhede M; Lewis KL; Calimeri T; Durot E; Renaud L; Øvlisen AK; McIlroy G; Ebsworth TJ; Elliot J; Santarsieri A; Ricard L; Shah N; Liu Q; Zayac AS; Vassallo F; Lebras L; Roulin L; Lombion N; Manos K; Fernandez R; Hamad N; Lopez-Garcia A; O'Mahony D; Gounder P; Forgeard N; Lees C; Agbetiafa K; Strüßmann T; Htut TW; Clavert A; Scott H; Guidetti A; Barlow BR; Tchernonog E; Smith J; Miall F; Fox CP; Cheah CY; El Galaly TC; Ferreri AJM; Cwynarski K; McKay P
Blood; 2022 Apr; 139(16):2499-2511. PubMed ID: 34995350
[TBL] [Abstract][Full Text] [Related]
4. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
[TBL] [Abstract][Full Text] [Related]
5. [Risk assessment and prophylactic treatment strategies for central nervous system relapse of diffuse large B-cell lymphoma].
Miyazaki K
Rinsho Ketsueki; 2023; 64(6):490-496. PubMed ID: 37407473
[TBL] [Abstract][Full Text] [Related]
6. Comparison of standardized prophylactic high-dose and intrathecal methotrexate for DLBCL with a high risk of CNS relapse.
Akimoto M; Miyazaki T; Takahashi H; Saigusa Y; Takeda T; Hibino Y; Tokunaga M; Ohashi T; Matsumura A; Teshigawara H; Suzuki T; Teranaka H; Nakajima Y; Matsumoto K; Hashimoto C; Fujimaki K; Fujita H; Sakai R; Fujisawa S; Nakajima H
Int J Hematol; 2024 Feb; 119(2):164-172. PubMed ID: 38233702
[TBL] [Abstract][Full Text] [Related]
7. Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trial.
Gleeson M; Counsell N; Cunningham D; Chadwick N; Lawrie A; Hawkes EA; McMillan A; Ardeshna KM; Jack A; Smith P; Mouncey P; Pocock C; Radford JA; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
Ann Oncol; 2017 Oct; 28(10):2511-2516. PubMed ID: 28961838
[TBL] [Abstract][Full Text] [Related]
8. Model for Predicting Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma and Discussion of Prophylaxis Measures.
Cui JY; Liu YF; Gao B; Mi L; Deng LJ; Zhu J; Hou SL
World Neurosurg; 2023 Nov; 179():e387-e396. PubMed ID: 37652134
[TBL] [Abstract][Full Text] [Related]
9. Timing of high-dose methotrexate CNS prophylaxis in DLBCL: an analysis of toxicity and impact on R-CHOP delivery.
Wilson MR; Eyre TA; Martinez-Calle N; Ahearne M; Parsons KE; Preston G; Khwaja J; Schofield J; Elliot J; Mula Kh A; Shah N; Cheung CK; Timmins MA; Creasey T; Linton K; Smith J; Fox CP; Miall F; Cwynarski K; McKay P
Blood Adv; 2020 Aug; 4(15):3586-3593. PubMed ID: 32761231
[TBL] [Abstract][Full Text] [Related]
10. Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse.
Bobillo S; Joffe E; Sermer D; Mondello P; Ghione P; Caron PC; Hamilton A; Hamlin PA; Horwitz SM; Kumar A; Matasar MJ; Batlevi CL; Moskowitz A; Noy A; Owens CN; Palomba ML; Straus D; von Keudell G; Dogan A; Zelenetz AD; Seshan VE; Younes A
Blood Cancer J; 2021 Jun; 11(6):113. PubMed ID: 34135307
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of prophylactic high-dose MTX in high-risk DLBCL: a treatment intent-based analysis.
Jeong H; Cho H; Kim H; Chae H; Lee JB; Lee K; Kim S; Lee SW; Ryu JS; Kim KW; Chae EJ; Huh J; Park CS; Yoon DH; Suh C
Blood Adv; 2021 Apr; 5(8):2142-2152. PubMed ID: 33881464
[TBL] [Abstract][Full Text] [Related]
12. Primary breast diffuse large B-cell lymphoma in the rituximab era: A retrospective study of the Chinese Southwest Oncology Group.
Weng H; Shrestha PR; Hong H; Chen Z; Yu L; Yao Y; Zhang Z; Zou L; Zhu B; Zhou H; Liu X; Liu Y; Guo H; Huang H; Lin T
Cancer Med; 2023 Dec; 12(23):21188-21198. PubMed ID: 37997571
[TBL] [Abstract][Full Text] [Related]
13. Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature.
Guirguis HR; Cheung MC; Mahrous M; Piliotis E; Berinstein N; Imrie KR; Zhang L; Buckstein R
Br J Haematol; 2012 Oct; 159(1):39-49. PubMed ID: 22849793
[TBL] [Abstract][Full Text] [Related]
14. Intrathecal methotrexate prophylaxis and central nervous system relapse in patients with diffuse large B-cell lymphoma following rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone.
Tomita N; Takasaki H; Ishiyama Y; Kishimoto K; Ishibashi D; Koyama S; Ishii Y; Takahashi H; Numata A; Watanabe R; Tachibana T; Ohshima R; Hagihara M; Hashimoto C; Takemura S; Taguchi J; Fujimaki K; Sakai R; Motomura S; Ishigatsubo Y
Leuk Lymphoma; 2015 Mar; 56(3):725-9. PubMed ID: 24913502
[TBL] [Abstract][Full Text] [Related]
15. A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma.
Cheah CY; Herbert KE; O'Rourke K; Kennedy GA; George A; Fedele PL; Gilbertson M; Tan SY; Ritchie DS; Opat SS; Prince HM; Dickinson M; Burbury K; Wolf M; Januszewicz EH; Tam CS; Westerman DA; Carney DA; Harrison SJ; Seymour JF
Br J Cancer; 2014 Sep; 111(6):1072-9. PubMed ID: 25072255
[TBL] [Abstract][Full Text] [Related]
16. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab.
Tai WM; Chung J; Tang PL; Koo YX; Hou X; Tay KW; Quek R; Tao M; Lim ST
Ann Hematol; 2011 Jul; 90(7):809-18. PubMed ID: 21229246
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of central nervous system prophylaxis with stand-alone intrathecal chemotherapy in diffuse large B-cell lymphoma patients treated with anthracycline-based chemotherapy in the rituximab era: a systematic review.
Eyre TA; Djebbari F; Kirkwood AA; Collins GP
Haematologica; 2020 Jul; 105(7):1914-1924. PubMed ID: 31488560
[TBL] [Abstract][Full Text] [Related]
18. Central nervous system (CNS) prophylaxis in antiCD20-CHOP treated DLBCL at intermediate to high risk for CNS relapse: A systematic review and meta-analysis.
Ho G; Tan C; de Mel S; Poon L; Chan EHL; Lee J; Liu X; Chng WJ; Chee YL; Soon YY; Jeyasekharan AD
Crit Rev Oncol Hematol; 2021 Nov; 167():103507. PubMed ID: 34656744
[TBL] [Abstract][Full Text] [Related]
19. Factors Influencing Physician Discretion to Administer CNS Prophylaxis in Diffuse Large B Cell Lymphoma: A Single Institution Retrospective Study.
Hino C; Lacy C; Brothers J; Cao H; Mirshahidi H; Park K; Akhtari M
Clin Lymphoma Myeloma Leuk; 2023 Oct; 23(10):764-771. PubMed ID: 37482525
[TBL] [Abstract][Full Text] [Related]
20. Optimization of high-dose methotrexate prophylaxis for central nervous system relapse in diffuse large B-cell lymphoma: a multicenter analysis.
Fang Y; Su N; Ma S; Cai J; Zhong L; Li W; Huang H; Li Z; Huang H; Xia Y; Liu P; Guo L; Li Z; Wu Y; Tian X; Wang J; Zhang Y; Cai Q
Ann Hematol; 2022 Mar; 101(3):595-605. PubMed ID: 34985557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
